This work, German Bundeswehr Reserve and U.S. Army Brigade Celebrate 40 Years of Military Cooperation and Friendship, by SGT Marvin Lopez, identified by DVIDS, must comply with the restrictions shown on https://www.dvidshub.net/about/copyright Beijing (Gasgoo)- Chinese new energy vehicle maker XPENG recently celebrated the delivery of its 10,000th vehicle in Europe according to the company's announcement on December 23 This makes XPENG the first Chinese battery-electric vehicle (BEV) startup to achieve this delivery milestone in the European market.   Starting its European journey in Norway in 2021 The company's high-tech and high-performance BEVs have filled gaps in the local new energy vehicle market establishing a reputation for "intelligent" and "premium" mobility solutions XPENG's European lineup is priced between €40,000 and €80,000 (approximately RMB 300,000–RMB 600,000).   At the "XPENG AI Day," Chairman and CEO He Xiaopeng emphasized that the key to international success for Chinese automakers lies not in cost-efficiency but in technological innovation XPENG leads the industry in over-the-air (OTA) update frequency The next overseas update will introduce German and French voice control services enhancing user experience across Europe.   XPENG also unveiled its latest overseas expansion plan at the Paris Motor Show targeting entry into over 60 countries and regions by the end of 2025 the company aims to make overseas markets contribute half of its total sales within the next decade underscoring its commitment to global growth.   Gasgoo not only offers timely news and profound insight about China auto industry, but also help with business connection and expansion for suppliers and purchasers via multiple channels and methods. Buyer service:buyer-support@gasgoo.comSeller Service:seller-support@gasgoo.com Share on FacebookShare on X (formerly Twitter)Share on PinterestShare on LinkedInCOOLIDGE AZ (AZFamily) — A World War II soldier who died nearly eight decades ago has been identified as an Arizona man The Defense POW/MIA Accounting Agency (DPAA) say the soldier that was killed in action was identified as U.S Shortly before midnight on New Year’s Eve in 1944 German troopers launched an attack known as Operation NORDWIND The German attack surged through Allied defenses The battle continued for the following weeks and Flores’ unit was assigned to a sector known as “Hoch Ebersberg” in France With no record of German troopers capturing Flores and no remains found the War Department issued a Report of Death in Jan a person using a metal detector discovered human remains while illegally collecting war relics from a foxhole in Hoch Ebersberg The witness found evidence that linked to the remains of the U.S The remains were sent to a DPAA lab for analysis Flores’ name is on the Walls of the Missing at Epinal American Cemetery in Dinozé A rosette will be placed next to his name to show he has been accounted for Flores will be buried in Tempe on August 3 See a spelling or grammatical error in our story? Please click here to report it Do you have a photo or video of a breaking news story? Send it to us here with a brief description Nicolas-Antoine Taunay was a prolific artist although he was to describe himself at the end of his life as a “painter of historical landscapes” his oeuvre (of more than a thousand paintings) shows that he was much more could be expressed by such a limited classification for the painting of the Battle of Nazareth He was particularly fond of military scenes producing renowned versions of The attack on the castello di Cossaria near Millesimo and The battle and taking of the city of Ebersberg not forgetting his rendering of the triumphal entry into Munich However he was to be best known for his representation of everyday life in the Grande Armée His vision of an episode during the Peninsular War The French army crossing the defiles of the Sierra Guadaramma  Taunay also tried Troubadour painting and painted many different sorts of genre painting His famous voyage to Brazil in the years 1816 to 1821 on a mission to found an academy of Fine Arts for his very rare panoramic views of Rio de Janeiro at the beginning of the 19th century The empress Josephine was very fond of this artist's paintings and his special skill at bringing anecdotal liveliness to his work Here the subject was short excursion made by the empress to Arona in June 1805 on the shores of Lago Maggiore The landscape takes the lion's share of the composition where a promontory is dominated by a monumental statue of San Carlo Borromeo the young women sitting down to sketch) seems very secondary the sense for detail and the extraordinary liveliness give the work a characteristic charm The painting was acquired by the French Musée national de Malmaison at an auction in April 2007 and it provides a partner for another painting by Taunay the Empress in Italy receiving news of a victory presented to the Salon of 1808 and which formed part of Josephine's own collection. Karine Huguenaud (tr Whether you are a private individual or a company you get tax benefits on donations to the Fondation Napoléon © Fondation Napoléon 2025 ISSN 2272-1800 LONDON (AP) — AstraZeneca's repeated missteps in reporting vaccine data coupled with a blood clot scare could do lasting damage to the credibility of a shot that is the linchpin in the global strategy to stop the coronavirus pandemic potentially even undermining vaccine confidence more broadly That may have provided "an incomplete view of the efficacy data," according to the statement which showed its shot was about 79% effective 17 but appeared to be consistent with more up-to-date data An independent panel that oversees the study scolded the company in a letter Monday for cherry-picking data according to a senior administration official health leaders that it was concerned the company chose to use data that was outdated and potentially misleading instead of the most recent findings who discussed the contents on the condition of anonymity given the sensitivity of the matter Even if the damage is limited to AstraZeneca itself it would have far-reaching effects since the shot is cheaper and easier to store than many of its rivals' and thus is expected to be widely used in the developing world International health agencies have repeatedly said the vaccine is safe and effective but it's not the first time the company has run into problems with public trust the European Union has complained about delays in vaccine deliveries from the company Then last week, more than a dozen countries temporarily halted their use of the AstraZeneca shot after reports of rare blood clots in some people who received it. The European Medicines Agency concluded the shot did not increase the overall incidence of clots but the unwanted attention appears to have left a mark a top official warned Monday it might not be able to resume its use of the vaccine because so many people were rejecting it vaccination coordinator Valeriu Gheorghita said 33,000 AstraZeneca immunization appointments had been canceled in 24 hours and that about a third of the 10,000 people scheduled to receive the vaccine did not show up a sprawling exhibition center set up for people to get the AstraZeneca vaccine was mostly deserted on Monday "This is unfortunately more about perception than it is the science," said Dr an infectious diseases specialist at Britain's University of Exeter that the AstraZeneca vaccine provides protection and is safe," he said "But the narrative for the public has not been as clear." France is a prime example of the confusion French President Emmanuel Macron initially suggested the vaccine wasn't effective for older people France only authorized AstraZeneca's vaccine for use in adults 65 and under But when there were reports of rare blood clots in some vaccine recipients the government suspended use of the shot all together The whiplash-inducing messages come at a time when France — like much of continental Europe — is struggling to speed up its vaccination drive while also facing a spike in cases that is close to overwhelming its hospitals and prompting threats of new lockdowns At a European Parliament committee Tuesday in Brussels head of the European Commission's health directorate described the situation with AstraZeneca as "a shame." She said the struggling vaccination campaigns across Europe were "made much more difficult by the bad performance of AstraZeneca." The company has blamed delays in its deliveries on production issues Even if the drugmaker clears up the latest misunderstanding a virologist at the University of Leicester pointed to the decades-old controversy over the measles vaccine as a cautionary tale The tepid support for the AstraZeneca vaccine in Europe stands in contrast to governments in the developing world that are desperate for supplies a senior adviser at the World Health Organization agency has a long list of countries "very keen" to get the shot as soon as possible "We simply cannot get enough of it," he said But some experts have worried that the skepticism in Europe could eventually cast a pall over the vaccine worldwide They suggested one measure that could reassure a jittery public: a green light from the U.S regulator looks at this data and authorizes AstraZeneca that will carry a lot of weight," said Jimmy Whitworth a professor of international public health at the London School of Hygiene and Tropical Medicine AstraZeneca said it would be submitting its data to the FDA within weeks It's still possible the vaccine can bury the doubts 68-year-old Rui Manuel Martins dismissed the concerns saying millions had been immunized with very few ill effects "There's always some cases of people rejecting any medications," he said before receiving his first dose "It's better to be vaccinated rather than not." WASHINGTON (AP) — Results from a U.S. trial of AstraZeneca’s COVID-19 vaccine may have included “outdated information” and that could mean the company provided an incomplete view of efficacy data American federal health officials said early Tuesday A spokesman from the drug company said Tuesday it was “looking into it.” AstraZeneca reported Monday that its COVID-19 vaccine provided strong protection among adults of all ages in a long-anticipated U.S a finding that some experts hoped would help rebuild public confidence in the shot around the world and move it a step closer to clearance in the U.S the company reported that the vaccine was found to be 79% effective at preventing symptomatic cases of COVID-19 — including in older adults There were no severe illnesses or hospitalizations among vaccinated volunteers compared with five such cases in participants who received dummy shots — a small number but consistent with findings from Britain and other countries that the vaccine protects against the worst of the disease AstraZeneca also said the study’s independent safety monitors found no serious side effects, including no increased risk of rare blood clots like those identified in Europe a scare that led numerous countries to briefly suspend vaccinations last week But just hours after those encouraging results were reported National Institute of Allergy and Infectious Diseases issued an unusual statement The agency said the Data and Safety Monitoring Board “expressed concern that AstraZeneca may have included outdated information from that trial which may have provided an incomplete view of the efficacy data.” “We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate up-to-date efficacy data be made public as quickly as possible,” the statement added The company aims to file an application with the Food and Drug Administration in the coming weeks and the government’s outside advisers will then publicly debate the evidence Authorization and guidelines for use of the vaccine in the United States will be determined by the FDA and Centers for Disease Control and Prevention after thorough review of the data by independent advisory committees BERLIN (AP) — Several German regions again suspendedAstraZeneca shotson Tuesday for people under 60 after new reports of unusual blood clots prompting Chancellor Angela Merkel to call an urgent meeting about the continued use of the coronavirus vaccine The European Medicines Agency said at the time that the benefits of vaccination outweigh the risk but it could not rule out a link between the shot and some unusual kinds of clots and recommended adding a warning about possible rare side effects Brandenburg state and the country's biggest made the decision to temporarily halt vaccinations for younger people after the country’s medical regulator said it had received additional reports of an unusual form of blood clot in the head in recent recipients of the AstraZeneca vaccine those areas are home to almost a third of the German population The Paul Ehrlich Institute said a total of 31 such blood clots were reported by March 29 out of some 2.7 million doses of AstraZeneca that have been administered across the whole of Germany so far Nine of the people died and all but two of the cases involved women is scrambling to ramp up its vaccine program which lags far behind those in Britain and the United States some 13.2 million people in the country had received at least one dose of vaccine On Monday, Canada suspended use of the AstraZeneca vaccine in people under 55 Deeks said the updated recommendations come amid new data from Europe that suggests the risk of blood clots is now potentially as high as one in 100,000 much higher than the one in one million risk believed before Two state-owned hospitals in Berlin announced Tuesday that they had stopped giving the AstraZeneca vaccine to female staff members under 55 The heads of five university hospitals in western Germany called for a temporary halt to the vaccine for all younger women said the suspension of AstraZeneca vaccines for younger people was done as a precaution we need to treat it carefully and wait for the talks taking place at the federal level,” said Kalayci The decision could affect appointments for tens of thousands of teachers and people with preexisting conditions who received invitations to get vaccinated in Germany's capital in recent days Appointments for the AstraZeneca shot were available sooner than ones for the vaccines made by Pfizer-BioNTech and Moderna German news agency dpa quoted a spokesman for Munich saying that the suspension of AstraZeneca vaccinations for people younger than 60 would last “until issue of possible vaccine complications for this group of persons has been resolved.” Scientists at the University of Greifswald this week published the results of their investigation into the possible causes of the blood clots saying the condition is similar to a side effect seen in some patients who receive the blood thinning medication heparin doesn't provide a conclusive explanation for why some people vaccinated with the AstraZeneca shot develop the rare blood clots experts not involved in the study said it offers important information to doctors a specialist in vascular diseases and blood clot research at the Medical University of Vienna an infection specialist at the University Hospital Regensburg in Germany cautioned that the generally low risk of death from COVID-19 in younger women could be similar to the risk of suffering a serious blood clot Some other European countries remain hesitant about giving the AstraZeneca shot to older people residents ages 60 to 65 started receiving the vaccine Tuesday ahead of those between the ages of 66 and 79 because Spanish authorities have not yet reviewed new data provided by AstraZeneca about how well it works in the older age group Spain is currently using the Pfizer-BioNTech and Moderna vaccines for people over 80 years old Spanish health authorities have said that they are hoping to speed up the rollout of vaccines with the arrival of the jab developed by the pharmaceutical company Janssen which has also been approved for use in Europe and requires one shot only LONDON (AP) — The European Medicines Agency is expected to provide updated guidance Friday on how countries across Europe should use the coronavirus vaccine developed by AstraZeneca. the Amsterdam-based drug regulator for the 27-nation European Union said there was a “possible link” between the AstraZeneca vaccine and rare blood clotting disorders but that the benefits of getting the shots outweighed the risks The EMA previously described the clots as “very rare” side effects and said the vaccine label's should be modified so doctors and patients are aware It’s still unclear how frequently the rare blood clots occur which has administered more AZ vaccine than any other country there were 30 such cases among 18 million doses Last month, more than a dozen countries, mostly in Europe, suspended their use of the AstraZeneca vaccine over the blood clot issue. Most restarted — some with age restrictions — after the EMA said countries should continue using the vaccine. The agency this week identified a similar possible link between blood clots and the COVID-19 vaccine developed by Johnson & Johnson the EMA recommended labeling changes but said the benefits of getting vaccinated outweighed the risks Toward Racial Justice: Voices from the Midstate AstraZeneca Covid-19 vaccine stand in a fridge at the locale vaccine center in Ebersberg near Munich (Pittsburgh) — This week, hundreds of thousands more Pennsylvanians have begun searching for COVID-19 vaccine appointments transit workers and those who live and work in prisons homeless shelters and domestic violence shelters are among some of the newly eligible people adding to the demand for shots By mid-April, every Pennsylvanian will be eligible to get jabbed. As manufacturers continue to ramp up production millions of doses of vaccine will flow into the commonwealth over the coming weeks But much of the supply chain infrastructure for the biggest vaccination effort in U.S. history is being built as the rollout progresses So how do doses get from manufacturer to clinic Here’s what we know about how it works in Pennsylvania Every dose of vaccine administered in the United States is allocated by the federal government into one of three different streams One stream goes to states and other jurisdictions to further allocate to providers Another goes to pharmacies participating in the federal partnership and the third goes to federally qualified health centers Walgreens or the East Liberty Family Health Care Center receive their vaccine supplies via a different process than UPMC Department of Health and Human Services has not disclosed how many vaccine doses go to pharmacy partners and FQHCs a spokesperson said that the doses controlled by states territories and cities represent the largest portion The number of doses that Pennsylvania gets to allocate is based on the portion of the state’s population over the age of 18 State health department communications director Barry Ciccocioppo said state officials have requested the maximum amount doses from the federal government since the vaccine rollout began in December the Pennsylvania Department of Health has had more than half a million doses to allocate to providers each week Once the federal government has told Pennsylvania officials how many doses they can expect in a given week the state health department allocates vaccines to providers How many vaccines a provider gets is based on a couple of factors The department determines a county’s need by looking at the number of COVID-19 deaths and how many residents are over the age of 65 officials consider a county’s total population and the number of COVID-19 cases Second, what is a provider’s capacity to administer vaccines? That is, how much did they request, and how effectively have they administered previous shipments of vaccine? The health department has ordered providers to administer 80% of their first doses within seven days of receiving them Hospital systems will request supply that gets sent to their flagship hospitals before shipping out to additional locations This can obscure the actual county-by-county distribution of doses making it look like one county is getting more vaccines than it actually is Once the state approves a number of doses for a provider manufacturers ship supply directly to provider intake facilities Shipments arrive to providers in boxes filled with dry ice and packaging protecting the trays of vaccine vials Providers often already know whose arms the doses are destined for director of pharmaceutical care services at Conemaugh Health System in Johnstown said there were instances where she first found out about shipments when a distributor like McKessen or Pfizer would send her a tracking number so that makes it a little difficult to plan ahead,” Gritzer said Providers now get a few days heads up on how much vaccine they can expect in part because vaccines are allocated and shipped on a weekly basis allocating and receiving vaccines lasts between 10 and 14 days That means ordering and shipment cycles overlap with one another and when providers submit requests for vaccine allotments they’re predicting how many doses they can administer two weeks out Gritzer said there were times when she didn’t learn about how many second doses to expect during one cycle before the next request form was due to the state she requested the same amount of second doses as the previous week hoping she got enough supply to vaccinate people whose appointments were already booked “Initially it was very haphazard,” said Debbie Albin assistant director of UPMC’s HC Pharmacy Central A spokesperson for the state department of health said processes are still being created as the rollout continues But hiccups in the distribution process can mean delayed vaccinations for Pennsylvanians For example, miscommunication with the state led some Pennsylvania providers to inadvertently administer second doses as first doses in February Even though providers have to request specific amounts as first and second doses it’s up to providers to separate and keep track of which vials are which The boxes are not labeled as first or second doses by the manufacturers because the vaccine ingredients are the same As the supply of vaccines increases in Pennsylvania, scheduling processes are able to firm up, according to Acting Health Secretary Alison Beam. Last week, the department said that supply is increasing quickly enough that providers can have more predictability about how many doses they will receive That would be a welcome change to providers like Conemaugh Memorial Medical Center “It becomes very difficult to plan a vaccination clinic when you only know a few days ahead of time that you’re going to be getting vaccines,” Gritzer said providers can finalize plans for clinics and get shots into arms Some providers bring the vaccines directly to patients; for example or the County Health Department bringing vaccines into senior high rises But the majority of Pennsylvanians will have to place the final piece of the vaccination puzzle themselves Pennsylvania does not have a central registration portal where providers can reach out to schedule appointments based on eligibility Eligible people must find their own providers and book appointments through different and separate provider websites Larger health systems, like UPMC and Allegheny Health Network, have announced dates for mass vaccination clinics in the area Appointments at daily clinics in Allegheny County can be found online at provider websites listed below: A full list of local vaccine providers is available at the Pennsylvania Health Department website. Elsewhere online, Pennsylvanians have offered help for those searching for open appointments.  A local Facebook group, Getting Pittsburgh Vaccinated has several administrators ready to help members find an open appointment All Pennsylvanians are eligible for a COVID-19 vaccine beginning April 19 Become a WITF sponsor today » We spotlight and uplift the creators around us Driving Directions Request a Tour LONDON (AP) — AstraZeneca said Friday that it intends to seek U.S. authorization for its COVID-19 vaccine in the “coming weeks," acknowledging a delay in the much-anticipated filing that had been expected by mid-April The Anglo-Swedish drugmaker revealed the new timetable as it released first-quarter financial results which showed that the company delivered 68 million doses of the vaccine to the U.K. European Union and other countries in the first three months of the year The company said it was continuing to work on its application to the U.S noting the “substantial size of the file" that will include data from U.S trials as well all other studies completed so far and real-world data collected from use of the vaccine in other countries Among the issues that will likely be addressed are indications that the vaccine is linked to rare blood clots Several countries have recommended that the shot be given only to older people because of the potential side effect Vaccine experts say the blood clots are very rare less than the blood clot risks of women taking birth control When AstraZeneca released data from its U.S company officials said they expected to apply for FDA authorization in the first half of April an FDA advisory committee will publicly debate the evidence behind the shots before the agency decides whether to allow emergency use said at the time that if the FDA authorizes the vaccine the company would deliver 30 million doses immediately followed by another 20 million within the first month The White House is feeling increasingly confident about the supply of the three vaccines already being administered in the U.S. — Pfizer, Moderna and Johnson & Johnson. The U.S. has also been under mounting pressure to share more of its vaccine supply with the world, as infection rates surge in countries like India and other countries struggle to get enough doses to protect their most vulnerable residents. More than 3.1 million people worldwide have died of COVID-19, including more than 572,000 in the U.S. More than half of U.S. adults have received at least one dose of vaccine, and the government expects to have enough supply for the entire population by early summer. AstraZeneca reported revenue of $275 million from deliveries of 68 million doses of the vaccine during the first quarter. AstraZeneca has pledged that it will deliver the vaccine on a non-profit basis as long as the pandemic lasts. The company said 30 million doses went to the EU, 26 million to the U.K., 7 million to Gavi, an alliance that secures vaccines for low-income countries, and 5 million to other nations. To date, AstraZeneca and partners such as the Serum Institute of India and Fiocruz in Brazil have supplied more than 300 million COVID-19 vaccine doses to over 165 countries, the Anglo-Swedish drugmaker said. The vaccine was developed by researchers at Oxford University, who licensed the technology to AstraZeneca in an effort to tap into the company’s global manufacturing and distribution capacity. AstraZeneca in turn authorizes other companies to produce the shots around the world. Wind gusts of 30+ mph along with afternoon and evening blowing dust, could reduce visibility. Weather MapsRadarAstraZeneca asks FDA to authorize COVID antibody treatmentby DANICA KIRKA and MATTHEW PERRONE Associated Press The Anglo-Swedish company said Tuesday that the treatment would be the first long-acting antibody combination to receive an emergency authorization for COVID-19 prevention the drug would likely be limited to people with compromised immune systems who don't get sufficient protection from vaccination Pangalos said the company's long-acting formulation is designed to boost immunity for up to one year compared with existing drugs that offer a month or two of protection The FDA has authorized three other antibody drugs including two that can be given after a possible COVID-19 exposure to head off symptoms AstraZeneca's drug would instead be given as a preventive measure in people who have increased vulnerability to the virus The FDA has stressed that antibody drugs are not a substitute for vaccination Antibody drugs also are expensive to produce and require an IV or injection and health care workers to administer Late-stage human trials showed that AstraZeneca's antibody drug reduced the risk of developing symptomatic COVID-19 by 77% More than three-quarters of the participants had suppressed immune systems due to cancer lupus and other conditions that made them more susceptible to severe disease Pangalos said the company's drug will provide "an additional option to help protect against COVID-19 alongside vaccines." The company will also seek regulatory authorization in Europe and other regions across the world The drugs are laboratory-made versions of virus-blocking antibodies that help fight off infections The treatments help the patient by supplying concentrated doses of one or two antibodies demand for the treatments soared over the summer where unvaccinated patients threatened to overwhelm hospitals The main antibody treatments being used in the U.S government has purchased bulk quantities of both drugs and oversees their distribution to the states AstraZeneca said it is in purchase talks with the U.S Pangalos said the company is capable of producing dose quantities in the "low millions." Shanghai (Gasgoo)- On the first day of 2025 Chinese smart electric vehicle maker XPeng Inc ("XPENG" or the "Company") announced its latest delivery performance marking a record-breaking monthly delivery volume for the fourth consecutive month an 82% year-on-year surge and a 19% month-on-month growth The XPENG MONA M03 model accounted for over 15,000 units while the XPENG P7+ recorded deliveries of more than 10,000 units XPENG achieved a record quarterly delivery of 91,507 vehicles exceeding the upper limit of its Q4 delivery guidance XPENG's annual deliveries in 2024 reached 190,068 units The MONA M03 model continued its robust growth in December marking the fourth straight month of deliveries exceeding 10,000 units the 50,000th MONA M03 rolled off the production line in December setting a new record as XPENG's fastest production rollout XPENG said its factory has significantly accelerated production capabilities now capable of rolling out one MONA M03 car every 72 seconds The Company also delivered over 10,000 units of the XPENG P7+ in December The month saw the second major over-the-air (OTA) update for the P7+ model with the XPENG XOS 5.5.0 entering public testing This update introduced a groundbreaking "car-to-parking" software feature with seamless This OTA marked XPENG's 373rd OTA update for 2024 XPENG achieved a significant milestone in December The Company also opened its first flagship store in Australia and began large-scale shipments of the XPENG G6 to the Australian market XPENG celebrated the one-year anniversary for the market launch of its high-end all-electric MPV The model has achieved cumulative sales of 21,642 units with 12 OTA updates rolled out throughout the year of 2024 Armstrong Williams takes on the news of the week and asks the questions you want answered. Don’t miss our weekly town hall. Dutch temporarily halt AstraZeneca shots for under-60sby MIKE CORDER Associated Press THE HAGUE, Netherlands (AP) — The Dutch government said Friday it is temporarily halting AstraZeneca coronavirus vaccinations for people under 60 following reports of very small number of people suffering unusual blood clots after receiving the shot The Dutch decision comes three days after authorities in Germany also stopped using the AstraZeneca’s vaccine in the under-60s citing fresh concerns over unusual blood clots reported in a tiny number of those who received the shots a Dutch organization that monitors vaccine side effects said it had received five reports of blood clots with low blood plate counts following vaccinations All the cases occurred between seven and 10 days after the vaccinations and all the people affected were women aged between 25 and 65 years The organization said in the period when the five cases were reported some 400,000 people were vaccinated in the Netherlands with the AstraZeneca shot Health Minister Hugo de Jonge says the temporary halt is a precautionary measure The news is another setback for the AstraZeneca vaccine which is critical to Europe’s immunization campaign and a linchpin in the global strategy to get shots to poorer countries for it is cheaper and easier to use than rival vaccines from Pfizer and Moderna It comes two weeks after the EU drug regulator said the vaccine does not increase the overall incidence of blood clots following a similar scare The European Medicines Agency said at the time that the benefits of vaccination outweigh the risks but it could not rule out a link between the shot and some unusual kinds of clots and recommended adding a warning about possible rare side effects resumed using the AstraZeneca vaccine on March 19 De Jonge said the Dutch pause comes ahead of an update next week from the EU medicines agency on the AstraZeneca vaccine A wave of COVID infections has been emerging in Germany for weeks this summer debunking claims that the pandemic is supposedly over the number of infections is constantly increasing and is now at the same level as at the beginning of the wave last autumn more people were ill at the beginning of July than ever before at this time of year According to figures from the Robert Koch Institute (RKI) 5.1 million people in Germany are currently suffering from acute respiratory diseases This means that the number of new respiratory infections is around 150 percent higher than before the pandemic Head of the Intensive Care Register of the German Interdisciplinary Association for Intensive Care and Emergency Medicine the evidence is “clear”: “A coronavirus summer wave is currently building up.” The infection radar of the Federal Health Ministry indicates a constantly rising viral load in all reported sewage treatment plants in recent weeks While it was still at 42,000 gene copies at the beginning of May it is now almost three times as high and stands at 119,000 gene copies the Health Ministry is also recording an increase in visits to the doctor due to COVID-19 infections head of the North Rhine Pharmacists’ Association told the Rheinische Post newspaper: “Respiratory infections are well above the usual level in the summer months the population’s defence mechanisms no longer seem to be as efficient since coronavirus the coronavirus is a fourth new major challenge for the immune defence.” Coronavirus tests are in high demand in pharmacies managing director of Krankenhausgesellschaft NRW explained that hospitals were also feeling the effects of the wave “We are currently experiencing a surprising increase in coronavirus infections for the summer season.” The increase was “moderate,” but “this development” was “naturally also reflected in inpatient cases in hospitals.” the hospitalisation incidence level due to COVID-19 cases rose from 0.4 per 100,000 in May to 1.4 in July This corresponds to around 1,170 hospitalisations per week The number of hospitalisations is therefore more than three times higher than at the same time last year These developments refute the claims of politicians and the media that the coronavirus has gone from a pandemic to an endemic state No serious scientist would ever describe the spread of a virus as endemic when over 10,000 people per week are hospitalised every year during the peak phase in winter and the virus does not disappear even during the “low phases,” with many hundreds still having to be admitted to hospital every week The consequences of the virus go far beyond immediate hospitalisations and deaths In contrast to acute respiratory diseases such as influenza or RSV one in 10 COVID-19 infections leads to long-term effects that can have devastating consequences and severely restrict the ability to work new and more infectious mutations emerge every year due to the unhindered spread of the virus The current summer wave is being driven by the Omicron sub-variants KP.2 and KP.3 which account for 13 percent and 52 percent of infections A compilation of the World Socialist Web Site's coverage of this global crisis Furthermore, because of the dismantling of all health protection measures by all government parties, it is only a matter of time before a more deadly variant develops or another pandemic breaks out. The risk of a devastating H5N1 bird flu pandemic is currently growing as well chief virologist at Berlin’s Charité hospital called the situation “confusing and worrying,” in the Süddeutsche Zeitung newspaper Although it was possible to get H5N1 under control he could “also imagine that we will soon be caught up in the next pandemic with H5N1.” In view of this situation, the debate in official politics and the media about a “reappraisal” of the coronavirus pandemic can only be described as criminal. As the WSWS has already commented this demand from the ruling class does not serve the purpose of serious scientific evaluation but rather the criminalisation of life-saving measures taken in the past There had been “decisions that were over the top,” said Chancellor Olaf Scholz (Social Democrats SPD) recently in the traditional “summer interview” by broadcaster ARD And Finance Minister Christian Lindner (Liberal Democrats FDP) denounced the COVID protection measures in the language of the far right as “encroachments on fundamental rights that were not justified.” but the fact that they were not consistently enforced internationally and were ended prematurely to keep the economy going and the profits flowing more than 183,000 people died in Germany alone It is this murderous “profits before lives” policy that needs a thorough “reappraisal.” The working class must settle accounts with this policy by fighting for a scientifically based Someone from the Socialist Equality Party or the WSWS in your region will contact you promptly Support responsible news and fact-based information today In an episode of Glenn Beck’s Blaze TV program that has been clipped and widely shared on Facebook and TikTok Beck holds up a stack of papers for the camera “This is 153 pages of the confidential agreement between Moderna and the U.S government and it goes back to 2015,” Beck says He then goes on to say that the papers reveal the U.S government has “ulterior motives” in mandating the coronavirus vaccines “Did you know the government co-owns the vaccine?… the same government that is now mandating its use owns the vaccine?” The video was flagged as part of Facebook’s efforts to combat false news and misinformation on its News Feed. (Read more about our partnership with Facebook.) Is it true that the government “owns the vaccine,” as Beck said But, as The New York Times reported Nov there is a long-brewing disagreement between Moderna and the National Institutes of Health over who developed a crucial part of the COVID-19 vaccine known as the mRNA sequence — and that could have implications for ownership of important patents related to the vaccine There are various patent applications related to this vaccine, and Public Citizen, an advocacy group, has been urging the government to assert its interests as inventors. Public Citizen said on Nov. 2 that Moderna left off government scientists in three patent applications and government scientists are credited as co-inventors on only one application The NIH neither owns, nor co-owns, the COVID-19 vaccine that was developed by Moderna and NIH, according to a statement from Mark L. Rohrbaugh the NIH special adviser for technology transfer But, as the Times reported, the NIH believes that three of its scientists worked with Moderna and played a major role in making important discoveries that led to the Moderna vaccine Moderna disagrees — and said so in a July filing with the U.S. Patent and Trademark Office; its patent application names its own employees as the sole inventors of the mRNA sequence which is considered the principal component of the vaccine A lot of money is at stake, as well as a big say in the distribution of vaccines worldwide. If the NIH scientists were named as inventors on the sequence patent, that would enable the government to collect royalties on the patent and to license it as it sees fit, including, some have noted to other vaccine manufacturers besides Moderna The result could have long-term consequences for global vaccine access In 2020, NIH scientists collaborated with Moderna to design and test the COVID-19 vaccine that Moderna manufactures and sells, known as mRNA-1273, Rohrbaugh said. The collaboration evolved from one originally focused on the development and testing of mRNA vaccines to combat the zoonotic virus Nipah and MERS a coronavirus related to SARS and SARS-CoV-2 The 2015 agreement that Beck appears to be citing in his video was between the NIAID and Moderna. It was an agreement to exchange confidential information to allow the parties to explore possible interest in collaborating In his video, Beck referenced a material transfer agreement among the University of North Carolina, NIAID, and Moderna, and said it was from 2015. However, that material transfer agreement was executed in 2019, according to the NIH, before SARS-CoV-2 had been identified as the cause of COVID-19 and its nucleotide sequence determined These materials emerged from NIAID’s collaboration with Moderna on the development of a MERS vaccine which NIH said pre-dates work on a vaccine specific to COVID-19 said that the NIH would share mRNA coronavirus vaccine candidates developed and jointly owned by NIAID and Moderna On Nov. 11 Moderna released a statement saying that it did not agree that government scientists “co-invented claims to the mRNA (modified nucleotide) sequence of our COVID-19 vaccine.” The statement continued: “Moderna remains the only company to have pledged not to enforce its COVID-19 intellectual property during the pandemic Moderna offered to resolve its dispute with NIAID by making the government co-owners of those patent applications that only listed Moderna scientists as inventors including the right as co-owners to license the patents as they see fit.” But Rohrbaugh said the disagreement reported in the Times relates to inventors listed on patent applications Moderna filed that cover the mRNA-1273 vaccine an intellectual property law scholar at Stanford Law School rejected the idea that the government has “ulterior motives” in mandating the vaccine “The government has paid billions of dollars to Moderna for the vaccine,” he said “And it has not shown favoritism toward Moderna over the Pfizer vaccine where there is no claim the government scientists were involved in the invention.” said that the United States does have some rights in the Moderna patented inventions already including patents already licensed to Moderna by the NIH and patents is challenging the decision by Moderna to exclude NIH employees as co-inventors Love also rejected the idea that the government has an ulterior motive for mandating the vaccine director of Knowledge Ecology International a nonprofit that works around the world to distribute knowledge resources in underserved places said that the United States is spending billions of dollars to buy the vaccine from Moderna and that it “spends more than it gets This fact check was originally published by PolitiFact, which is part of the Poynter Institute. It is republished here with permission. See the sources for this fact check here and more of their fact checks here Most Americans aren’t at risk of a fentanyl overdose and seizure data doesn’t tell the full story With the exception of the Houston Chronicle this year’s Pulitzers largely left legacy metro papers behind the Pulitzers recognize outstanding journalism The Pulitzer board honored ProPublica for a second year running this time for exposing the fatal consequences of vague abortion exceptions The winning series — produced as part of a New York Times local investigations fellowship — explores Baltimore’s fentanyl crisis Get the Poynter newsletter that's right for you You don't have permission to access the page you requested What is this page?The website you are visiting is protected.For security reasons this page cannot be displayed Chinese smart electric vehicle maker XPENG achieved remarkable milestones that solidified its presence in smart mobility and innovation The company expanded its footprint into key international markets while marking the delivery of its 10,000th vehicle in Europe Strengthening its collaboration with Volkswagen XPENG advanced the co-development of electronic & electrical (E/E) architecture and software reinforcing its commitment to global partnerships Technological innovation was at the forefront with groundbreaking advancements in smart driving and AI such as the debut of the AI-powered Tianji OS and the tape-out of its self-developed TURING chip The company also made strides in flying car development launching its "Land Aircraft Carrier" project and breaking ground on a manufacturing base through its affiliate company XPENG AEROHT showcasing its ability to cater to diverse market demands These accomplishments set the stage for an in-depth look at XPENG's transformative year XPENG opens first automobile store in Australia XPENG announced the grand opening of its first automobile store in Australia The store features the XPENG G6 model and the company's flying car as its centerpiece exhibits XPENG achieves milestone with 10,000th BEV delivered in Europe XPENG celebrated the delivery of its 10,000th vehicle in Europe This makes XPENG the first Chinese battery-electric vehicle (BEV) startup to achieve this delivery milestone in the European market.  XPENG puts XPENG X9 MPV model onto Thai market XPENG announced in early December that the XPENG X9 had officially hit the Thai market a Twitter-like social media platform in China XPENG AEROHT, Hainan Province team up on pilot applications of flying cars the eVOLT aircraft (flying car) company affiliated to XPENG and the Hainan Provincial Development and Reform Commission signed a strategic cooperation framework agreement to establish a "Flying Car Application Demonstration Island" in Hainan according to XPENG AEROHT's announcement XPENG enters UK market by signing dealership agreement with IML XPENG entered into a partnership with International Motors Ltd a renowned automotive dealer group in Europe according to a post on XPENG's WeChat account The agreement designates IML as XPENG's official distributor in the UK a market long considered a crucial gateway for Chinese automakers entering Europe XPENG launches industry's first crowdfunding campaign for chip upgrade XPENG announced the launch of the industry's first-ever crowdfunding campaign for a chip upgrade XPENG P7+ hits market, starting at 186,800 yuan XPENG officially released the XPENG P7+ AI-powered sedan onto the market on November 7 the P7+ includes a Long Range version priced at 186,800 yuan an Ultra Long Range version at 198,800 yuan XPENG unveils latest power, AI tech advancements at XPENG AI DAY unveiling an extensive range of innovations and its flying car and robotics technology This event highlighted XPENG's commitment to becoming a global AI-driven automaker over the next decade with a strong emphasis on expanding internationally XPENG AEROHT breaks ground on flying car manufacturing base in Guangzhou officially commenced construction of its flying car manufacturing base in Guangzhou This facility will focus on producing components for its modular flying car the "Land Aircraft Carrier," with a planned annual production capacity of 10,000 units XPENG launches G6, G9 models in UAE the launch of its G6 and G9 models in the United Arab Emirates (UAE) held in collaboration with Ali & Sons Holding LLC in Dubai signifies XPENG's official entry into the UAE market furthering its strategic presence in the region XPENG AEROHT secures 300-million-yuan preorder contract for 150 units of 'Land Aircraft Carrier' XPENG AEROHT announced strategic partnerships with Gaozhi Aviation and Aocheng Aviation ("Gaozhi" and "Aocheng" are Chinese Pinyin) at the 3rd Global Digital Trade Expo securing a pre-order contract for 150 units of its "Land Aircraft Carrier" flying car worth nearly 300 million yuan ($40 million) XPENG completes tape-out of self-developed TURING chip XPENG celebrated its 10th anniversary in Beijing where it announced its strategic vision for the next decade aiming to become a global AI automotive company The event also marked the official market launch of XPENG's intelligent A major highlight of the event was the unveiling of "XPENG TURING," the world's first chip designed for simultaneous application in robots This groundbreaking chip successfully completed its tape-out process on August 23 XPENG MONA M03 hits market, starting at 119,800 yuan XPENG officially put the MONA M03 compact sedan the first production model under its fire new MONA series offering three different trim levels priced from 119,800 yuan to 155,800 yuan The Max version would start deliveries after the Chinese New Year holiday in 2025 XPENG G6 model goes on sale in Thai market unveiling the right-hand-drive version of its XPENG G6 the first model XPENG introduced into the Thai market XPENG AEROHT, HRC step up cooperation on tech R&D, volume production for flying car XPENG AEROHT signed a deep strategic cooperation agreement with HRC a global leading composite material solutions supplier Building on their existing successful partnership the two companies aim to further advance their collaboration focusing on advanced lightweight materials This partnership will encompass both current models and future planned models reinforcing their leadership in the low-altitude flight sector XPENG AEROHT secures $150 million in Series B1 funding XPENG AEROHT announced it has secured $150 million in Series B1 funding and has simultaneously initiated the Series B2 funding The company stated that this round of financing would ensure the smooth progress of XPENG AEROHT's flying car R&D XPENG unveils latest smart car technology results including AI-powered Tianji XOS 5.2 XPENG held the XPENG Smart AI Technology Conference in Guangzhou where it officially launched the AI-powered Tianji XOS 5.2 in-car OS and announced its global rollout to all eligible XPENG models XPENG announces foray into Singaporean market with pop-up store opened XPENG officially entered the Singaporean market with a pop-up store opened at the UOB Plaza in the heart of Singapore's Central Business District XPENG AEROHT, Hechi city join hands to promote testing, applications of flying cars officially signed a strategic cooperation agreement to jointly promote key aspects of flying car development according to a post on XPENG AEROHT's WeChat account XPENG, Volkswagen Group ink agreement for joint development of E/E architecture XPENG and Volkswagen Group announced the signing of a joint development agreement for electronic and electrical (E/E) architecture This follows their former strategic cooperation framework agreement signed on April 17 XPENG offers global debut of MONA M03 all-electric car the first production model under XPENG's fire new MONA series while its interior details remain confidential The MONA M03 targets the 100,000-yuan to 150,000-yuan market with the official market release scheduled for August XPENG launches G9, P7 models in Egypt XPENG held a press conference at the Grand Egyptian Museum in Cairo to launch the XPENG G9 and P7 models in the Egyptian market These two products would be delivered to Egyptian customers by the end of this month making XPENG the first Chinese smart electric vehicle brand to introduce pure electric vehicle models to Egypt and Africa Autoliv, XPENG AEROHT partner for development of flying car technologies Autoliv China and XPENG AEROHT signed a strategic cooperation agreement in Guangzhou Driven by their shared commitment to future mobility safety the duo would collaborate on various initiatives aimed at advancing the development of flying car technology jointly developing safety solutions for future mobility XPENG launches mass-produced end-to-end large model where it announced the rollout of the AI Tianji in-car OS to all existing XPENG models XPENG introduced China's first mass-produced end-to-end large model XPENG announces foray into French market with launch of XPENG G9 model XPENG held a launch event for the XPENG G9 model in Paris marking its official entry into the French market XPENG launches AI-powered Tianji OS for intelligent driving, smart cockpit XPENG launched its all-new AI-powered Tianji OS at the Auto China 2024 This marks the industry's first comprehensive application of AI technology in both intelligent cockpits and smart driving systems XPENG announces foray into Australian market XPENG on May 11 announced an exclusive cooperation agreement with Australia's TrueEV marking its official entry into the Australian market BorgWarner forms two new eMotor projects with XPENG BorgWarner officially revealed two business agreements with XPENG to supply high-voltage hairpin (HVH) eMotor systems for two forthcoming SUV models These contracts encompass BorgWarner's oil-cooled 800V eMotor systems tailored with stator and rotor components designed specifically for these vehicles XPENG to adopt RoboSense's MX LiDAR for intelligent driving application the provider of LiDAR and perception solutions announced a partnership with China's leading smart electric vehicle company This collaboration aims to explore the scale-production of advanced driver assistance systems (ADAS) based on RoboSense's next-generation mid-to-long-range LiDAR The goal is to allow more consumers to experience safer and more convenient intelligent mobility XPENG AEROHT plans to build take-off and landing sites for flying car demonstration the Panyu District People's Government of Guangzhou City and XPENG AEROHT an urban air mobility company and a subsidiary of XPeng Inc signed the "Framework Agreement to Jointly Promote the Application of Flying Cars" the two parties jointly announced the initiation of infrastructure construction for flying cars planning to establish the first four take-off and landing sites in the Guangzhou Higher Education Mega Center (HEMC) XPENG announces foray into China's Hong Kong, Macao markets XPENG announced its official entry into the Hong Kong market XPENG has partnered with Sime Darby Motors and appointed the latter as its official agent for new car sales and aftersales services in Hong Kong XPENG announces foray into German market XPENG announced its official entry into the German market with the Launch ("Shangshi" in Chinese Pinyin) Edition of the G9 and P7 models introduced at the same time according to the Chinese automaker's WeChat post XPENG announces foray into ASEAN market during the 45th Bangkok International Motor Show Chinese smart electric vehicle maker XPENG announced a long-term strategic partnership with Neo Mobility Asia This collaboration marks XPENG's official entry into the Association of Southeast Asian Nations ("ASEAN") market signifying a crucial step in its global expansion strategy XPENG AEROHT's 'Land Aircraft Carrier' flying car enters airworthiness certification phase the urban air mobility company affiliated with XPeng Inc. officially announced that the application for the Type Certificate (TC) of its "Land Aircraft Carrier" flying car's airframe (codenamed: X3-F) had recently been accepted by the Civil Aviation Administration of China (CAAC) South Central Regional Administration indicating that the model is poised to enter the airworthiness certification phase XPENG rolls out 'Infinite XNGP' intelligent driving feature to experienced users XPENG announced its immediate rollout of the "Infinite XNGP (XPENG Navigation Guided Pilot) Intelligent Assisted Driving" feature to experienced intelligent driving function users This innovative feature would be available across all cities and routes where navigation is supported Volkswagen Group, XPENG ink master agreement on co-development of platform, software Volkswagen Group and XPENG jointly announced that they have entered into a Master Agreement on Platform and Software strategic technical collaboration ("Master Agreement") marking a further milestone following XPENG’s news releases dated July 26 2023 in connection with the Volkswagen's acquisition of 4.99% shareholding in XPENG and the signing of the framework agreement on strategic technical cooperation the focus of the latest technical cooperation revolves around the joint development of two B-segment battery electric vehicle (BEV) models under the Volkswagen brand XPENG forays into UAE market by teaming up with local dealer Ali&Sons XPENG declared a strategic partnership with the UAE dealership group This collaboration marks a significant step in XPENG's international expansion With a focus on deploying cutting-edge technology XPENG aims to introduce intelligent electric vehicles to local consumers through partnerships with high-quality overseas dealers XPENG renovates Zhaoqing plant's production line for upcoming new car model In a ceremony held at the Guangdong Zhaoqing factory in late Jan. XPENG launched the renovation of its production line for a new vehicle model aims to enhance the existing vehicle production line at the Zhaoqing base to prepare for the production of the upcoming vehicle The comprehensive modification project for the new vehicle model line involves a total investment exceeding a billion yuan The entire process is expected to take approximately 20 days The project is progressing steadily according to the plan with the goal of completing all transformation tasks by February 9 and finishing overall production line debugging by the end of February XPENG's first MPV model X9 hits market, starting at 359,800 yuan marking the company's entry into the MPV segment The X9 lineup includes four trim levels priced between 359,800 yuan and 419,800 yuan with deliveries set to commence this month #29293a);margin:auto;margin-top:32px;max-width:calc(640px + (2 * 12px));padding:0 12px;}@media screen and (min-width: 768px){.css-9uetne{margin-top:72px;}}.css-1lgqo8v{color:var(--sz-basic-text-color-primary 10:50 Uhr.css-rhp0z0{color:var(--sz-basic-border-color-secondary #c0c1c6);display:inline-block;margin:0 12px;}|.css-13l0r79{display:inline-block;}Lesezeit: 3 Min .css-y4bre2{display:block;height:auto;width:100%;}.js .css-y4bre2{cursor:pointer;}.css-1hdpxq{-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;background-color:rgb(255 #fff);display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;height:inherit;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;-webkit-transform:translateY(100%);-moz-transform:translateY(100%);-ms-transform:translateY(100%);transform:translateY(100%);-webkit-transition:-webkit-transform 600ms cubic-bezier(0.23 1);transition:transform 600ms cubic-bezier(0.23 #fff);padding:8px 12px 0;color:var(--sz-basic-text-color-primary #29293a);font-family:'SZSansDigital','Neue Helvetica','Helvetica',sans-serif;font-size:0.875rem;line-height:1.5;}.css-1vyk908 p{display:inline;}.css-1vyk908 small{color:var(--sz-basic-text-color-secondary #71737f);}.css-1vyk908 small{display:block;}.css-1vyk908 a{border-bottom:1px solid var(--sz-basic-text-color-primary #29293a);color:var(--sz-basic-text-color-primary #29293a);padding-bottom:2px;-webkit-text-decoration:none;text-decoration:none;-webkit-transition:border-bottom 150ms ease-in-out;transition:border-bottom 150ms ease-in-out;}.css-1vyk908 a:focus,.css-1vyk908 a:hover{border-bottom-color:transparent;}Marc Block Vorsitzender des Ärztlichen Kreisverbands Ebersberg kritisiert die Bedarfsplanung der Kassenärztlichen Vereinigung Bayern als zu unpräzise sagt der Koordinierungsarzt des Landkreises Marc Block Von Johanna Feckl Als Marc Block am Mittwochnachmittag nach einem Besuch am Ebersberger Volksfestplatz wieder in seinem Auto sitzt sagt der Zornedinger Hausarzt und Koordinierungsarzt der niedergelassenen Arztpraxen im Kreis am Telefon das zu sehen!" Ein Team des Ebersberger Bauhofs steckte bereits mitten in den Vorbereitungen um die Volksfesthalle in ein provisorisches Impfzentrum zu verwandeln: Am Samstag werden dort wo für gewöhnlich im Sommer viele Arme Masskrüge in die Höhe stemmen viele Arme für Impfungen mit dem Vakzin Astra Zeneca blank gezogen - so hofft es zumindest Marc Block 1000 Dosen des Impfstoffs und ein Team an medizinischem Personal stehen von acht bis 20 Uhr für alle Impfwilligen ab 18 Jahren bereit Interessierte können ohne vorherige Anmeldung vorbeikommen die jeweilige Impf-Priorisierung spielt keine Rolle "Unser Impfzentrum und die Arztpraxen führen lange Listen von Impfwilligen " dass selbst Menschen ohne Impfstoff-Präferenzen oft lange auf einen Termin warten müssten Zum anderen seien Praxen mittlerweile überwiegend mit Themen rund ums Impfen gegen Corona beschäftigt - andere Belange würden in den Hintergrund geraten dass Praxen meistens zunächst ihre eigenen Patienten und Patientinnen impfen - wer also keinen Hausarzt hat Und zuletzt fehle bei einigen Impfwilligen die technische Affinität um sich online beim Impfportal zu registrieren "Deshalb schaffen wir am Samstag ein zusätzliches und sehr niederschwelliges Impfangebot" Die Impf-Sonderaktion in Ebersberg ist großem Engagement zu verdanken und wird die Quote im Landkreis höchstwahrscheinlich deutlich verbessern Grundlose Beschwerden sind da völlig fehl am Platz Die Unterlagen können über die Homepage des Landratsamts heruntergeladen werden Daneben werden die Krankenkassenkarte und ein gültiger Personalausweis oder Reisepass benötigt sowie der Impfpass Ein Aufklärungsgespräch vor Ort findet in jedem Fall statt es musste alles recht schnell gehen mit der Organisation "Die Sommerferien stehen ja bald vor der Türe" dass viele Menschen ihren Urlaub kein zweites Mal im heimischen Garten zwischen Wäscheständer und Lampignons auf dem Balkon oder am See um die Ecke verbringen wollen - die Ferne ruft Denn wenn der Impfschutz idealerweise vor den Sommerferien vollständig gewährleistet sein soll zwischen Erst- und Zweitimpfung aber ein gewisser zeitlicher Abstand gewahrt werden muss dann kommt Block zufolge eigentlich nur der bevorstehende Samstag als Aktionstag in Frage Die Ständige Impfkommission empfiehlt bei Astra Zeneca einen Zeitraum von zwölf Wochen zwischen den Spritzen entstammen aus einer zusätzlichen Impfstoff-Lieferung "Astra Zeneca ist im Moment wesentlich leichter zu bekommen" Fünf Teams bestehend aus einem Arzt oder einer Ärztin sowie einem oder zwei medizinisch-technischen Fachkräften sind für die Impfungen zuständig Nach drei Stunden endet eine Schicht und fünf neue Teams beginnen ihre Arbeit insgesamt werden also gut 60 Menschen im Einsatz sein - alle Beteiligten verrichten ihren Dienst übrigens in ihrer Freizeit Ob sich genügend Freiwillige gemeldet haben konnte Block am Mittwochnachmittag noch nicht abschließend sagen "Ich habe heute aber schon sehr viele Zusagen bekommen und bin optimistisch "Entscheidend in der jetzigen Phase der Pandemie ist teilt eine Sprecherin aus dem Landratsamt mit Die Impf-Aktion findet statt am Samstag, 15. Mai, von acht bis 20 Uhr am Ebersberger Volksfestplatz für Impfwillige ab 18 Jahren. Die benötigten Unterlagen zur Impfung gibt es online unter lra-ebe.de/aktuelles/informationen-zum-corona-virus/gernimpfzentrum/ zum Download In anspruchsvollen Berufsfeldern im Stellenmarkt der SZ. .css-5x0u19{-webkit-text-decoration:none;text-decoration:none;}Gutscheine.css-pcxqtt{border:0;clip:rect(0 0 0 0);height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute;white-space:nowrap;width:1px;}: At the beginning of the coronavirus pandemic we were told that we were all in this together Why are COVID-19 vaccines scarce? One critical reason is secrecy. Pharmaceutical corporations fiercely guard their COVID-19 vaccine recipes as trade secrets — despite receiving billions in taxpayer funding to come up with those recipes Yet Moderna has scaled up manufacturing relatively slowly but otherwise protecting the secret vaccine recipe from competitors Even in the face of an epochal public health crisis Moderna has focused on selling vaccines to the world’s richest countries It has declined to share vaccine recipes more broadly even as infections skyrocket and death counts accelerate in Brazil President Biden has two existing but as-yet unused legal tools that could bring Moderna to the negotiating table and help end the pandemic Biden can leverage both tools to demand that Moderna share its trade secrets with the US government and with vaccine manufacturers around the world the US government has a legal right to sue Moderna for patent infringement Based on an analysis that one of us just published the government could demand over a billion dollars in compensation based on Moderna’s 2021 US sales projections alone — a significant cut of Moderna’s profits Moderna’s sales in 2022 and beyond will likely be at risk for additional patent infringement liability providing the US government additional leverage to coax Moderna While Pfizer and Johnson & Johnson could also be compelled under the DPA the patent is particularly powerful leverage over Moderna Biden ran on the promise of ending the pandemic but has yet to release a plan for global vaccine access. He can help the world produce billions of more vaccine doses this year. The alternative is an unconscionable loss of life. Nobody should have a monopoly over the knowledge needed to end a pandemic. This is no time for secrets. Christopher Morten is a registered patent attorney and deputy director of the Technology Law and Policy Clinic at New York University School of Law. Christian Antonio Urrutia is an AIDS activist and cofounder of PrEP4All. Zain Rizvi is a law and policy researcher at Public Citizen. Home Delivery Gift Subscriptions Log In Manage My Account Customer Service Delivery Issues Feedback News Tips Help & FAQs Staff List Advertise Newsletters View the ePaper Order Back Issues News in Education Search the Archives Privacy Policy Terms of Service Terms of Purchase Work at Boston Globe Media Internship Program Co-op Program Do Not Sell My Personal Information securing the services of Florian Niederlechner The 32-year-old striker will join the Blue-Whites from FC Augsburg in the summer and has signed a contract until 2025 “We are pleased that we have been able to bring Florian Niederlechner to Hertha BSC we are getting an experienced attacker who brings a goal threat as well as a good mentality and physicality He has regularly proven all of this in the Bundesliga in the last few years,” said Fredi Bobic 65 direct goal involvements in the Bundesliga Niederlechner has up until now made 181 Bundesliga appearances for 1 scoring 44 times and getting a further 21 assists He has also scored four times and made seven assists in 19 DFB-Pokal appearances numbers that the Ebersberg-born forward would like to build on during his time in Berlin Our German-speaking fans can stay on the ball with the Hertha BSC newsletter Sign up today and you will receive a 10% welcome discount 14:40 Uhr.css-rhp0z0{color:var(--sz-basic-border-color-secondary #c0c1c6);display:inline-block;margin:0 12px;}|.css-13l0r79{display:inline-block;}Lesezeit: 2 Min Im Messerattacke-Prozess von Grafing-Bahnhof ist das Urteil gesprochen worden wurde für nicht schuldfähig erklärt und kommt nun in eine geschlossene Psychiatrie Er habe "nicht den geringsten Zweifel" am damaligen Krankheitszustand des 28-Jährigen Eine "drastische Vergeltungsstrafe" sei hier nicht geeignet hatte bereits am ersten Verhandlungstag gestanden ein 59-jähriger Mann aus Grafing ist seither halbseitig gelähmt Letztlich sei die dauerhafte Unterbringung in der geschlossenen Klinik "eine der schärfsten Sanktionen kommt nun in eine psychiatrische Einrichtung und ist dort im sogenannten Maßregelvollzug untergebracht so soll die Allgemeinheit geschützt sein und der Heilungsprozess des Täters gefördert werden Wie lange er in der Psychiatrie bleiben muss die Hürden für eine Entlassung sind jedoch sehr hoch Erst bei einer eindeutig günstigen Prognose durch forensische Sachverständige ist eine Entlassung auf Bewährung möglich die Stadt sei "von Muslimen ausgerottet" als er vor 14 Monaten einen Menschen tötete und drei schwer verletzte Die Details zur Tat klingen wie aus dem Drehbuch eines Horrorfilms Mai 2016 im Wahn ohne Vorwarnung auf vier Menschen am S-Bahnhof in Grafing eingestochen ein 56-Jähriger starb nach neun Messerstichen im Krankenhaus damals unter dem Einfluss seiner Krankheit gehandelt hat einer bipolaren affektiven Störung und einer Schizophrenie was in der Grafinger Nacht eine Art Verfolgungswahn auslöste In den Plädoyers wurden zwei allgemeine Probleme angesprochen, die in dem zweiwöchigen Prozess zur Sprache kamen der seit der Messerattacke halbseitig gelähmt ist dass ihr Mandant bisher keinerlei Opferentschädigung vom Staat erhalten habe Dass damit bis nach dem Prozess gewartet werde "Letztlich sind Täter und Tat hinreichend bekannt" der Anwalt des beim Angriff verletzten Manfred M. erinnerte an die körperlichen und psychischen Folgen für die Opfer keinesfalls eine Bewährung in Betrachtung zu ziehen Paul H.s Verteidiger Florian Alte kritisierte rechtzeitig unterzubringen und möglicherweise die Tat zu verhindern" war in seinem Heimatort Gießen in Hessen sechsmal in einer Psychiatrie Kurz bevor er vor gut einem Jahr dann nach München aufbrach hatte ihn ein junger Polizist in Hessen als nicht gefährlich für sich und die Gesellschaft eingestuft und so eine Einweisung verhindert dass Menschen wie der Beamte Entscheidungen treffen müssen hatte bereits am ersten Prozesstag ein umfangreiches Geständnis abgelegt und bei allen Opfern entschuldigt Dabei schaute er den beiden überlebenden Opfern im Gerichtssaal und den Angehörigen des verstorbenen Wasserburgers Siegfried W ich wäre in der Klinik geblieben und hätte meine Medikamente genommen." Medical staff prepares an AstraZeneca coronavirus vaccine during preparations at the vaccine center in Ebersberg near Munich Waiving patents would permit increased manufacturing of COVID-19 vaccines and boost the monumental task of immunizing people around the world.(Matthias Schrader/AP Photo) Canada’s minister for international trade says the country is “ready to discuss” proposals to waive intellectual property protection for COVID-19 vaccines under a World Trade Organization (WTO) agreement that allows poorer countries to circumvent patent protections in public health emergencies The WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) established a minimum level of protection for intellectual property Article 8 of the agreement recognizes the rights of countries to adopt measures for public health and other public interest reasons and to prevent the abuse of intellectual property rights provided that such measures are consistent with the provisions of the TRIPS Agreement “Our government firmly believes in the importance of protecting IP (intellectual property) and recognizes the integral role that industry has played in innovating to develop and deliver life-saving COVID-19 vaccines,” Mary Ng said in a statement on Friday “Canada is ready to discuss proposals on a waiver for intellectual property (IP) protection Minister of International Trade Mary Ng participates in a news conference on the Canada-United Kingdom Trade Continuity Agreement in Ottawa announced Wednesday it will lift patent protections for COVID-19 vaccines to potentially allow international production a move that could aid developing countries’ vaccination efforts The European Union has also expressed willingness to lift intellectual property rights for COVID-19 vaccines European Commission President Ursula von der Leyen said on Thursday “Since the introduction of the IP waiver proposal Canada has actively worked with partners to identify barriers to vaccine access—many of which are unrelated to IP such as supply chain constraints,” Ng said “We remain committed to finding solutions and reaching an agreement that accelerates global vaccine production and does not negatively impact public health.” Oxfam Canada’s director of Policy and Campaigns said while the announcement by Ng is “a step in the right direction,” the world needs is “a full backing by Canada to waive intellectual property protections for COVID-19 vaccines.” “This waiver will pave the way for increasing the global supply of vaccines and will fundamentally alter the trajectory for the world’s poorest and most vulnerable to escape the depths of the pandemic,” Sarosi said “Today’s statement by the Government of Canada continues their wait and see approach and downplays IP as a barrier to supply problems Canada continues to prioritize profits over public health.” an industry group that represents some pharmaceutical companies It “will not address the real issues of trade barriers global supply chain bottlenecks and scarcity of raw materials that are impacting the supply of COVID-19 vaccines,” it said in a statement A woman receives the AstraZeneca vaccine for COVID-19 at a hospital in Prayagraj In hopes of taming a monstrous spike in COVID-19 infections India opened vaccinations to all adults Saturday launching a huge inoculation effort that was sure to tax the limits of the federal government the country’s vaccine factories and the patience of its 1.4 billion people have previously asked fellow WTO members to agree to a time-limited lifting of COVID-19-related intellectual property rights as the virus has spread in developing nations that have been unable to execute strong vaccination campaigns The World Health Organization said in April that of 700 million vaccines administered around the world only 0.2 per cent had been in low-income countries any decision by the WTO has to be agreed upon by all 164 members and negotiations within the international trade body have historically taken up to months to complete a strong advocate for equitable access to vaccines and medical supplies around the world through our support for the Access to COVID-19 Tools (ACT) Accelerator and the COVAX Facility,” Ng said we have announced $940 million to support low- and middle-income countries to access COVID-19 vaccines and treatments because we understand that the pandemic isn’t over anywhere All rights reserved @ Radio Canada International 2018 This website is using a security service to protect itself from online attacks The action you just performed triggered the security solution There are several actions that could trigger this block including submitting a certain word or phrase You can email the site owner to let them know you were blocked Please include what you were doing when this page came up and the Cloudflare Ray ID found at the bottom of this page The fatal accident took place at around noon on Wednesday. According to emergency services, a car with German licence plates was travelling towards Schengen when it left the road and struck a tree. The force of the collision caused the car to slide into a nearby ditch. The driver, a 48-year-old German man from Bavaria Ebersberg, died of his injuries. Following the incident, the CR152 road was closed in both directions while the wreckage was cleared. The cause of the collision remains unknown. EvacuationWeapon used in Kirchberg scare was fakeMan armed with fake gun caused commotion at bank branch on Monday Schengen AreaLuxembourg hopes for dialogue with Germany over border checksTens of thousands of people commute to work in Luxembourg every day Job searchBeen job-hunting unsuccessfully for more than six months? If you’ve had several months of rejection letters or never made it beyond first interviews, here’s what you might be doing wrong Financial scandalSpuerkeess rejects blame in Caritas embezzlement case Representatives tell parliament that the bank followed all internal procedures with its client PoliticsGermany in political chaos after Merz loses chancellor voteMerz fell short with 310 votes out of the required 316 Skin healthThe hype surrounding skincare routines“Seven steps to perfect skin” - skincare is a popular social media topic. But what really works? BrexitPremiumEU set to make it easier for UK professionals to work in the blocBrussels due to propose legislation to enable the recognition of qualifications of British lawyers and others AcquisitionLuxembourg recruitment firm Cyberr acquires French firm in move to double growth Platform dedicated to recruiting cybersecurity experts added 14 employees through acquisition Advertiser contentTreat yourself to a stress-free holidayDreaming of a worry-free trip What if the secret to a smooth getaway was simply good preparation and the right protection Advertiser contentReal estate: Why should you take advantage of the start of 2025 to begin your real estate project?The main things we remember about the housing sector over the past 12 months are the rise in interest rates and the fall in property prices Advertiser contentProperty: I've decided to invest!The various forms of government support for investment Advertiser contentThe Luxembourg Times BusinessRun is happening again on 18th September!On Thursday 18th September with the starting gun of the 11th Luxembourg Times BusinessRun fired at the Coque at 7 pm Share this with instagramShare this with facebookShare this with linkedinSections